0XOD Stock Chart & Stats
$41.04
-$0.69(-1.68%)
At close: 4:00 PM EDT
$41.04
-$0.69(-1.68%)
Day’s Range― - ―
52-Week Range$15.92 - $51.11
Previous CloseN/A
Volume273.00
Average Volume (3M)1.88K
Market Cap
$2.11B
Enterprise Value$1.94K
Total Cash (Recent Filing)$107.97M
Total Debt (Recent Filing)$196.13M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Nov 05, 2026EPS Estimate
0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.98
Shares Outstanding48,880,566
10 Day Avg. Volume1,305
30 Day Avg. Volume1,875
Financial Highlights & Ratios
PEG Ratio-0.94
Price to Book (P/B)-10.68
Price to Sales (P/S)10.26
P/FCF Ratio-6.92
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$60.20Price Target Upside46.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.71
Revenue Forecast (FY)$322.20M
Bulls Say, Bears Say
Bulls Say
ZUSDURI Commercial LaunchZUSDURI is showing meaningful early commercial traction, with revenue growth accompanied by broader account activation, more prescribers, and increasing repeat use. This expanding adoption base can support durable product revenue and establish a second commercial growth engine beyond JELMYTO.
Strong Product EconomicsRapid revenue growth combined with consistently high gross margins indicates attractive underlying economics for the commercial portfolio. If operating investment becomes more efficient as products scale, the company has a foundation to convert increasing gross profit into improved earnings and cash generation.
Pipeline And Platform ExpansionThe IntraGel transaction expands UroGen’s oncology pipeline and adds a sustained-release delivery platform that may support multiple localized cancer therapies. These rights broaden future product opportunities and reinforce the company’s strategic focus on differentiated drug-delivery technologies.
Bears Say
Persistent Cash BurnMaterially negative operating and free cash flow means the business continues consuming substantial cash despite revenue growth. Until profitability and cash generation are achieved, UroGen may have less flexibility to fund commercialization and development internally, increasing dependence on available capital.
Leveraged Balance SheetNegative equity and rising debt indicate limited balance-sheet flexibility while losses continue. Higher obligations can increase interest costs and constrain capital allocation, making successful commercialization and a timely path to profitability more important to the company’s financial resilience.
High Investment And Execution RiskUroGen is accelerating commercialization and development spending before the durability of ZUSDURI demand is fully established. The higher expense base can prolong losses, while the absence of full-year guidance reflects uncertainty around adoption trends and makes execution against profitability targets more demanding.
Urogen Pharma News
0XOD FAQ
What was Urogen Pharma’s price range in the past 12 months?
Urogen Pharma lowest share price was $15.92 and its highest was $51.11 in the past 12 months.
What is Urogen Pharma’s market cap?
Urogen Pharma’s market cap is $2.11B.
When is Urogen Pharma’s upcoming earnings report date?
Urogen Pharma’s upcoming earnings report date is Nov 05, 2026 which is in 43 days.
How were Urogen Pharma’s earnings last quarter?
Urogen Pharma released its earnings results on Aug 05, 2026. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.265 by -$0.015.
Is Urogen Pharma overvalued?
According to Wall Street analysts Urogen Pharma’s price is currently Undervalued.
Does Urogen Pharma pay dividends?
Urogen Pharma does not currently pay dividends.
What is Urogen Pharma’s EPS estimate?
Urogen Pharma’s EPS estimate is 0.1.
How many shares outstanding does Urogen Pharma have?
Urogen Pharma has 48,880,566 shares outstanding.
What happened to Urogen Pharma’s price movement after its last earnings report?
Urogen Pharma reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.265. Following the earnings report the stock price went up 15.824%.
Which hedge fund is a major shareholder of Urogen Pharma?
Currently, no hedge funds are holding shares in GB:0XOD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Urogen Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$60.20 (46.69% Upside)
$60.20 (46.69% Upside)
Blogger Sentiment
Bullish
GB:0XOD Sentiment 86%
Sector Average 63%
Sector Average 63%
Insider Transactions
Sold Shares
Worth $2.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
137.68%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
21.02%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Urogen Pharma
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
0XOD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong positive momentum driven by the ZUSDURI launch (Q2 ZUSDURI revenue of $50.4M, rapid growth in activated accounts and prescribers, durable Phase III durability data, pipeline progress, favorable IP outcomes and materially higher total revenue). Management acknowledged measured near-term risks including continued operating expense increases, quarter-to-quarter variability, remaining net loss (though substantially improved), and early-stage adoption dynamics. They reinforced confidence in cash sufficiency to reach profitability while accelerating investments to support long-term growth.View all GB:0XOD earnings summaries0XOD Stock 12 Month Forecast
Average Price Target
$60.20
▲(46.69% Upside)
Technical Analysis
Geron
―
Arbutus Biopharma
―
Phathom Pharmaceuticals
―
Taysha Gene Therapies
―
Zenas BioPharma, Inc.
―